In case you missed it...Seeking AlphaScouting for asymmetric opportunities in the small caps universe, I discovered Bioniche Life Sciences (US listing: BNHLF, Toronto: BNC.TO). This company is: •A full-fledged Phase III biotech. The test results were so good that FDA has allowed Bioniche to file for market approval in Q1 2015. •Addressing a $1 billion large and critically unmet medical need in bladder cancer with a ground-breaking technology. •About to receive an Orphan Drug Designation. •Fully funded. Bioniche has ample cash, and virtually no debt. You would expect such a company to be valued at $150 million minimum. That's a minimum, most Phase III biotechs are valued much higher. Not so in this case: the market values Bioniche at a mere $25 million. This doesn't make any sense. Bioniche is so ridiculously undervalued - exceptionally low valuation for a Phase III biotech stock - that it could be today's most undervalued biotech stock on the market. But I bet you never heard of Bioniche. Only 30 people are registered to receive email alerts on Seeking Alpha and there is no research to be found anywhere on the internet. If you're looking for a stock that is completely off-the-radar, Bioniche is. This article is the first research on Bioniche ever available for you to read, and explains why this is a genuine 10-bagger opportunity from current price levels.